Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $10.85 to $11.55
• 50-Day Range: $8.71 to $12.58
• 52-Week Range: $7.80 to $28.09
• Volume: 368,592 shs
• Average Volume: 308,532 shs
• Market Capitalization: $622.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.86
• Consensus Rating: Buy

Bicara Therapeutics Stock Analysis - MarketRank™

Bicara Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 717th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Bicara Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bicara Therapeutics is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bicara Therapeutics is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bicara Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BCAX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicara Therapeutics does not currently pay a dividend.

Dividend Growth

Bicara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BCAX.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.66

News Sentiment

Bicara Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $17.42 on January 1st, 2025. Since then, BCAX shares have decreased by 34.5% and is now trading at $11.41.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.04.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Who are Bicara Therapeutics' major shareholders?

Top institutional shareholders of Bicara Therapeutics include Geode Capital Management LLC (1.23%), Schroder Investment Management Group (0.78%), Artisan Partners Limited Partnership (0.74%) and Nan Fung Trinity HK Ltd. (0.63%).
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bicara Therapeutics: $31.86
• High Price Target: $48.00
• Low Price Target: $8.00
• Potential Upside/Downside: +179.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.67%
• Return on Assets: -20.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.80
• Quick Ratio: 24.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.98 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 54,560,000
• Free Float: 46,083,000
• Market Cap: $622.53 million
• Optionable: N/A
• Beta: N/A